Breaking News Instant updates and real-time market news.

PTCT

PTC Therapeutics

$21.17

-0.44 (-2.04%)

17:29
09/06/17
09/06
17:29
09/06/17
17:29

PTC Therapeutics assumed with an Equal Weight at Barclays

Barclays assumed PTC Therapeutics with an Equal Weight rating and a $22 price target, saying that while Translarna and Emflaza have showed steady growth, their high expectations are largely priced into PTC shares.

  • 06

    Sep

  • 28

    Sep

  • 24

    Oct

PTCT PTC Therapeutics
$21.17

-0.44 (-2.04%)

07/03/17
SBSH
07/03/17
NO CHANGE
Target $18
SBSH
Buy
PTC announced favorable data for RG7916, says Citi
After attending the Cure SMA Conference this weekend, Citi analyst Joel Beatty says favorable early clinical spinal muscular atrophy data presented by Roche (RHHBY) was suggestive that RG7916 will advance into the pivotal portion of its trials in the second half of 2017. This would trigger a $20M milestone from Roche to PTC Therapeutics (PTCT), Beatty tells investors in a research note. The analyst sees the data as de-risking and keeps a Buy rating on PTC shares.
07/20/17
SBSH
07/20/17
NO CHANGE
Target $28
SBSH
Buy
PTC Therapeutics price target raised to $28 from $18 at Citi
Citi analyst Joel Beatty raised his price target for PTC Therapeutics to $28 saying he still sees "multiple paths" to U.S. approval of Translarna. He expects the stock to trade up into the FDA panel meeting on September 28. The analyst values PTC's base business at $17 per share and pipeline at $11. Beatty maintains a Buy rating on PTC.
08/23/17
WBLR
08/23/17
INITIATION
Target $17
WBLR
Market Perform
PTC Therapeutics initiated with a Market Perform at William Blair
William Blair analyst Raju Prasad started PTC Therapeutics with a Market Perform rating and $17 fair value estimate, contending that it is not wise to view the FDA's demonstration of leniency for other rare disease therapies as raising the probability of success for ataluren, which he assigns only a 10% chance of success.
09/04/17
SBSH
09/04/17
NO CHANGE
Target $28
SBSH
Buy
Congressman supporting approval of PTC's DMD treatment, says Citi
Citi analyst Joel Beatty found comments online from U.S. Congressman Collin Peterson that voice support for approval of PTC Therapeutics' (PTCT) Duchenne muscular dystrophy treatment ataluren, which is also known as Translarna. The document appears to have been posted last Thursday in response to the FDA's request for comments regarding its advisory panel meeting scheduled for September 28, and is written in the form of a speech to be given at the meeting, Beatty told investors Friday night in a research note. The analyst confirmed from the Congressman's office that a legislative assistant plans to read the letter on behalf of Rep. Peterson at the September 28 advisory meeting. The comments mention a constituent of Rep. Peterson's with DMD who will be in the audience and for whom "access to ataluren has allowed him to live and thrive well into his 20s with no side effects," Beatty cites the statement as saying. It added, "The full consideration of ataluren not only fulfills the Congressional intent of FDASIA and the 21st Century Cures Act, but also has the potential to save lives across the nation." Beatty believes political support could play a role in the FDA's review of Translarna. The analyst notes that Sarepta Therapeutics' DMD drug Exondys 51 was approved after favorable political support. Beatty sees $20 of upside potential in PTC shares, with only $3 downside risk, around the FDA panel meeting. The analyst has a Buy rating on the shares with a $28 price target. The stock closed Friday up 18c to $20.93. A positive panel vote will likely lead to FDA approval while a negative vote doesn't necessarily mean the FDA will not approve the drug, Beatty argues. His model assumes a 25% probability of success for Translarna.

TODAY'S FREE FLY STORIES

BURL

Burlington Stores

$104.94

-1.61 (-1.51%)

07:55
11/22/17
11/22
07:55
11/22/17
07:55
Recommendations
Burlington Stores analyst commentary  »

Burlington Stores price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WYNN

Wynn Resorts

$158.57

1.61 (1.03%)

, MLCO

Melco Resorts & Entertainment

$26.31

0.13 (0.50%)

07:54
11/22/17
11/22
07:54
11/22/17
07:54
Recommendations
Wynn Resorts, Melco Resorts & Entertainment, Las Vegas Sands, MGM Resorts analyst commentary  »

UBS raises Macau…

WYNN

Wynn Resorts

$158.57

1.61 (1.03%)

MLCO

Melco Resorts & Entertainment

$26.31

0.13 (0.50%)

LVS

Las Vegas Sands

$67.79

0.71 (1.06%)

MGM

MGM Resorts

$33.34

0.16 (0.48%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GES

Guess

$17.95

0.17 (0.96%)

07:53
11/22/17
11/22
07:53
11/22/17
07:53
Technical Analysis
Technical View: Guess drops sharply after results and guidance »

The stock was last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UIS

Unisys

$7.55

0.25 (3.42%)

07:53
11/22/17
11/22
07:53
11/22/17
07:53
Hot Stocks
Unisys selected by New Zealand Ministry of Education for resourcing system »

Unisys has been selected…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Dec

QADA

QAD Inc.

$39.95

1.75 (4.58%)

07:51
11/22/17
11/22
07:51
11/22/17
07:51
Recommendations
QAD Inc. analyst commentary  »

QAD Inc. price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CYTK

Cytokinetics

$8.25

-2.85 (-25.68%)

07:48
11/22/17
11/22
07:48
11/22/17
07:48
Downgrade
Cytokinetics rating change  »

Cytokinetics downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRM

Salesforce

$108.80

1.43 (1.33%)

07:46
11/22/17
11/22
07:46
11/22/17
07:46
Recommendations
Salesforce analyst commentary  »

Salesforce price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

07:45
11/22/17
11/22
07:45
11/22/17
07:45
General news
U.S. MBA mortgage market index rose 0.1% »

U.S. MBA mortgage market…

CYTK

Cytokinetics

$8.25

-2.85 (-25.68%)

07:43
11/22/17
11/22
07:43
11/22/17
07:43
Recommendations
Cytokinetics analyst commentary  »

Cytokinetics price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DE

Deere

$139.23

2.31 (1.69%)

07:43
11/22/17
11/22
07:43
11/22/17
07:43
Technical Analysis
Technical View: Deere at new 52-week high after results beat expectations »

The stock was last at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Nov

  • 28

    Nov

CRM

Salesforce

$108.80

1.43 (1.33%)

07:42
11/22/17
11/22
07:42
11/22/17
07:42
Recommendations
Salesforce analyst commentary  »

Salesforce price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

07:40
11/22/17
11/22
07:40
11/22/17
07:40
General news
Treasury Market Outlook: longer dated bond yields are modestly higher »

Treasury Market Outlook:…

AXTA

Axalta Coating

$33.87

0.33 (0.98%)

07:39
11/22/17
11/22
07:39
11/22/17
07:39
Technical Analysis
Technical View: Axalta Coating up on Nippon Paint takeover talks »

The company earlier…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRM

Salesforce

$108.80

1.44 (1.34%)

07:39
11/22/17
11/22
07:39
11/22/17
07:39
Recommendations
Salesforce analyst commentary  »

Canaccord has 'no…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

OSUR

OraSure

$16.55

2.59 (18.55%)

07:36
11/22/17
11/22
07:36
11/22/17
07:36
Recommendations
OraSure analyst commentary  »

OraSure contract win…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GME

GameStop

$16.73

0.29 (1.76%)

07:35
11/22/17
11/22
07:35
11/22/17
07:35
Technical Analysis
Technical View: GameStop trades higher after earnings and outlook »

The stock was last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NUAN

Nuance

$14.67

0.15 (1.03%)

07:35
11/22/17
11/22
07:35
11/22/17
07:35
Recommendations
Nuance analyst commentary  »

In-line guidance likely…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

AAPL

Apple

$173.14

3.16 (1.86%)

, BAC

Bank of America

$26.73

-0.01 (-0.04%)

07:35
11/22/17
11/22
07:35
11/22/17
07:35
Options
Unusual call flow in option market yesterday »

Notable call activity was…

AAPL

Apple

$173.14

3.16 (1.86%)

BAC

Bank of America

$26.73

-0.01 (-0.04%)

MU

Micron

$49.40

1.76 (3.69%)

T

AT&T

$34.33

-0.31 (-0.89%)

ORCL

Oracle

$48.63

-0.39 (-0.80%)

AKS

AK Steel

$4.85

0.22 (4.75%)

PG

Procter & Gamble

$88.72

0.45 (0.51%)

TRIP

TripAdvisor

$32.81

2.33 (7.64%)

PEP

PepsiCo

$116.05

1.14 (0.99%)

PAGP

Plains GP Holdings

$20.48

-0.41 (-1.96%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 29

    Nov

  • 19

    Dec

EKSO

Ekso Bionics

$4.13

1.21 (41.44%)

07:33
11/22/17
11/22
07:33
11/22/17
07:33
Technical Analysis
Technical View: Ekso Bionics trades sharply higher, edging 52-week high »

The stock was last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTNX

Nutanix

$30.20

0.5 (1.68%)

07:32
11/22/17
11/22
07:32
11/22/17
07:32
Initiation
Nutanix initiated  »

Nutanix initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 30

    Nov

  • 07

    Dec

  • 12

    Dec

HPE

HP Enterprise

$14.12

0.03 (0.21%)

07:32
11/22/17
11/22
07:32
11/22/17
07:32
Recommendations
HP Enterprise analyst commentary  »

HP Enterprise CEO…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Nov

  • 11

    Dec

GE

General Electric

$17.83

-0.15 (-0.83%)

, DKS

Dick's Sporting

$28.58

-0.52 (-1.79%)

07:30
11/22/17
11/22
07:30
11/22/17
07:30
Options
Unusual put flow in option market yesterday »

Notable put activity was…

GE

General Electric

$17.83

-0.15 (-0.83%)

DKS

Dick's Sporting

$28.58

-0.52 (-1.79%)

ROST

Ross Stores

$72.67

-0.07 (-0.10%)

ILG

ILG

$28.11

-0.5 (-1.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Nov

  • 30

    Nov

  • 01

    Dec

  • 12

    Dec

DLTR

Dollar Tree

$99.46

2.35 (2.42%)

07:29
11/22/17
11/22
07:29
11/22/17
07:29
Recommendations
Dollar Tree analyst commentary  »

Dollar Tree price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

07:28
11/22/17
11/22
07:28
11/22/17
07:28
General news
Futures above fair value ahead of holiday »

Stock futures are…

SHOO

Steven Madden

$39.80

-0.6 (-1.49%)

07:28
11/22/17
11/22
07:28
11/22/17
07:28
Conference/Events
Steven Madden management to meet with Buckingham »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 28

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.